Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIS 420915 in familial amyloid polyneuropathy
2012-001831-30Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Nov 2012
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in familial amyloid polyneuropathy (FAP) comparing ISIS 420915 with Placebo (2 arms). Primary endpoints: Change in modified Neuropathy Impairment Score +7 and Change in Norfolk Quality of Life-Diabetic Neuropathy total score. Started Nov 2012; status: completed.
02
Drugs
inotersen
03
Conditions
familial amyloid polyneuropathy (FAP)
Beyond the preview
Go deeper on 2012-001831-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001831-30.